Expression of MicroRNA-1281, C-Reactive Protein, and Renal Function in Individuals with Abdominal Aortic Aneurysm and their Clinical Correlation after Endovascular Repair.

Lais Missae,Edwaldo Edner Joviliano,Maurício Serra Ribeiro,Emanuel Junio Ramos Tenorio,Daniela Tirapelli,Breno Rossoni

doi:10.21470/1678-9741-2020-0268

Abstract

Introduction:The treatment of infrarenal aortic aneurysms has changed in the last three decades. Endovascular aneurysm repair (EVAR) has become the primary treatment option in anatomically suitable patients with infrarenal aortic aneurysms. However, there is no serum biomarker to be used in EVAR follow-up.Methods:This is a prospective single-centre study of 30 consecutive patients with abdominal aortic aneurysm (AAA) who underwent EVAR. Serum dosages of micro ribonucleic acid 1281 (miRNA-1281), creatinine, total cholesterol, triglycerides, and C-reactive protein (CRP) were evaluated and angiotomographic evaluations were performed preoperatively and six months after the intervention.Results:There was a hyperexpression of miRNA-1281 in patients with AAA and a significant reduction of it after EVAR, from 1.66-fold before EVAR to 0.27 after the procedure (P<0.0001). MiRNA-1281 expression was not influenced by renal function (creatinine: 1.14±0.29, P=0.68), total cholesterol (179.9±59.9, P=0.22), or CRP (1.17±3.5; P=0.48). There is correlation between AAA size and CRP serum levels, however there was no statically significant reduction of CRP after EVAR.Discussion:MiRNA-1281 expression may be influenced by cholesterol, triglycerides levels, and renal function. We found no difference in these markers before and six months after EVAR. However, miRNA-1281 presents a significant reduction in patients with no follow-up complications. We hypothesize that miRNA-1281 expression may be related to aortic wall stress or flow changes.Conclusion:MiRNA-1281 may contribute as a possible marker of EVAR follow-up.

Highlights

The treatment of infrarenal aortic aneurysms has changed in the last three decades
There was a hyperexpression of miRNA-1281 in patients with abdominal aortic aneurysm (AAA) and a significant reduction of it after Endovascular aneurysm repair (EVAR), from 1.66-fold before EVAR to 0.27 after the procedure (P
MiRNA-1281 may contribute as a possible marker of EVAR follow-up

Summary

Introduction

The treatment of infrarenal aortic aneurysms has changed in the last three decades. The prevalence of abdominal aortic aneurysm (AAA) depends on associated risk factors that include advanced age, male gender, white race, positive family history, smoking, hypertension, hypercholesterolaemia, peripheral vascular occlusive disease, and coronary artery disease. Endovascular aneurysm repair (EVAR) has become the primary treatment option in anatomically suitable patients with infrarenal aortic aneurysms. The therapeutic success of EVAR is closely related to the evolution of renal function, which may compromise the results regarding the morbidity and mortality of the treatment. The monitoring of its evolution is fundamental to optimise the results and to detect possible complications or therapeutic failure[3]

Objectives

Methods

Results

Discussion

Conclusion